Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 2: 251 - 259

DOI: https://doi.org/10.19852/j.cnki.jtcm.2024.02.002

Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth via downregulating the Wnt/β-catenin pathway

  • Junli CHANG ,
  • Fulai ZHAO ,
  • Xingyuan SUN ,
  • Xiaoping MA ,
  • Peng ZHAO ,
  • Chujie ZHOU ,
  • Binhao SHI ,
  • Wenchao GU ,
  • Yongjun WANG ,
  • Yanping YANG
Expand
  • 1 Spine Disease Institute, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    2 Department of Diagnostic and Interventional Radiology, University of Tsukuba, Ibaraki 315-0114, Japan

Received date: 2023-01-11

  Accepted date: 2023-04-27

  Online published: 2024-03-05

Supported by

National Key R&D Program of China: Cooperating Studies on Measurement Technologies of Human Phenome and Cross-scale Correlation of Phenotypic Data(2020YFE0201600);National Nature Science Foundation: Study on LncRNA-CCDC18-AS1 Mediated Osteosarcoma Occurrence by Activating YAP/TAZ and Tumor Microenvironment M2 TAM-dependent Lung Metastasis, and Efficacy/mechanism of Removing Blood Stasis/clearing heat/eliminating Toxic Material Principle(81973877);Mechanism Study on m6A Methyltransferase RBM15 Mediated YAP Epigenetic Modification to Promote Osteosarcoma Lung Metastasis through Lymphatic System and Management with Qichong Powder(82174408);Shanghai Collaborative Innovation Center of Industrial Transformation of Hospital TCM Preparation: Preclinical Study on the Treatment of Osteosarcoma with Qingre Jiedu Granules;Research Projects within Budget of Shanghai University of Traditional Chinese Medicine: the Research on the Mechanism of the HIPK3 Activation of Wnt/β-catenin Induction the Osteosarcoma and the Intervention of Banmao Decoction(2021LK047)

Fold

Abstract

OBJECTIVE: To investigate the synergistic effects of polyphyllin I (PPI) combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on the growth of osteosarcoma cells through downregulating the Wnt/β-catenin signaling pathway.

METHODS: Cell viability, apoptosis and cell cycle distribution were examined using cell counting kit-8 and flow cytometry assays. The morphology of cancer cells was observed with inverted phase contrast microscope. The migration and invasion abilities were examined by xCELLigence real time cell analysis DP system and transwell assays. The expressions of poly (adenosine diphosphate-ribose) polymerase, C-Myc, Cyclin B1, cyclin-dependent kinases 1, N-cadherin, Vimentin, Active-β-catenin, β-catenin, p-glycogen synthase kinase 3β (GSK-3β) and GSK-3β were determined by Western blotting assay.

RESULTS: PPI sensitized TRAIL-induced decrease of viability, migration and invasion, as well as increase of apoptosis and cell cycle arrest of MG-63 and U-2 OS osteosarcoma cells. The synergistic effect of PPI with TRAIL in inhibiting the growth of osteosarcoma cells was at least partially realized through the inactivation of Wnt/β-catenin signaling pathway.

CONCLUSION: The combination of PPI and TRAIL is potentially a novel treatment strategy of osteosarcoma.

Key words： osteosarcoma; tumor necrosis factor-related apoptosis-inducing ligand; Wnt signaling pathway; beta-catenin; polyphyllin I

Cite this article

Junli CHANG , Fulai ZHAO , Xingyuan SUN , Xiaoping MA , Peng ZHAO , Chujie ZHOU , Binhao SHI , Wenchao GU , Yongjun WANG , Yanping YANG . Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth via downregulating the Wnt/β-catenin pathway[J]. Journal of Traditional Chinese Medicine, 2024 , 44(2) : 251 -259 . DOI: 10.19852/j.cnki.jtcm.2024.02.002

References

1. Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: accelerating progress makes for a hopeful future. Front Oncol 2018; 8: 4.
2. Ligon JA, Choi W, Cojocaru G, et al. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes. J Immunother Cancer 2021; 9: e001772.
3. Miwa S, Shirai T, Yamamoto N, et al. Current and emerging targets in immunotherapy for osteosarcoma. J Oncol 2019; 2019: 7035045.
4. Tsukamoto S, Errani C, Angelini A, Mavrogenis AF. Current treatment considerations for osteosarcoma metastatic at presentation. Orthopedics 2020; 43: e345-8.
5. Anderson ME. Update on survival in osteosarcoma. Orthop Clin North Am 2016; 47: 283-92.
6. Eaton BR, Schwarz R, Vatner R, et al. Osteosarcoma. Pediatr Blood Cancer 2021; 68: e28352.
7. Gamie Z, Kapriniotis K, Papanikolaou D, et al. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Lett 2017; 409: 66-80.
8. Zhao J, Lu Y, Shen HM. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett 2012; 314: 8-23.
9. Deng X, Yi X, Huang D, et al. ROCK2 mediates osteosarcoma progression and TRAIL resistance by modulating O-GlcNAc transferase degradation. Am J Cancer Res 2020; 10: 781-98.
10. Singh D, Prasad CB, Biswas D, et al. TRAIL receptors are differentially regulated and clinically significant in gallbladder cancer. Pathology 2020; 52: 348-58.
11. Moon MH, Jeong JK, Seo JS, et al. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp Mol Med 2011; 43: 138-45.
12. Shankar S, Ganapathy S, Srivastava RK. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res 2008; 14: 6855-66.
13. Tian Y, Gong GY, Ma LL, Wang ZQ, Song D, Fang MY. Anti-cancer effects of polyphyllin I: an update in 5 years. Chem Biol Interact 2020; 316: 108936.
14. Wang Q, Zhou X, Zhao Y, et al. Polyphyllin I ameliorates collagen-induced arthritis by suppressing the inflammation response in macrophages through the NF-κB pathway. Front Immunol 2018; 9: 2091.
15. Li K, Zhang J, Tian Y, et al. The Wnt/β-catenin/VASP positive feedback loop drives cell proliferation and migration in breast cancer. Oncogene 2020; 39: 2258-74.
16. Zhang LN, Zhao L, Yan XL, Huang YH. Loss of G3BP1 suppresses proliferation, migration, and invasion of esophageal cancer cells via Wnt/β-catenin and PI3K/AKT signaling pathways. J Cell Physiol 2019; 234: 20469-84.
17. Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol 2020; 13: 165.
18. He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomed Pharmacother 2020; 132: 110851.
19. Gajos-Michniewicz A, Czyz M. WNT signaling in melanoma. Int J Mol Sci 2020; 21: 4852.
20. Liu Y, Liu YZ, Zhang RX, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Int J Oncol 2014; 45: 795-803.
21. Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 2017; 169: 985-99.
22. Wiese KE, Nusse R, van Amerongen R. Wnt signalling: conquering complexity. Development 2018; 145: dev165902.
23. Ono M, Yin P, Navarro A, et al. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci USA 2013; 110: 17053-58.
24. Chang J, Wang H, Wang X, et al. Molecular mechanisms of polyphyllin I-induced apoptosis and reversal of the epithelial-mesenchymal transition in human osteosarcoma cells. J Ethnopharmacol 2015; 170: 117-27.
25. Chang J, Li Y, Wang X, et al. Polyphyllin I suppresses human osteosarcoma growth by inactivation of Wnt/β-catenin pathway in vitro and in vivo. Sci Rep 2017; 7: 7605.
26. Gallego-Lleyda A, De Miguel D, Anel A, Martinez-Lostao L. Lipid nanoparticles decorated with TNF-related aptosis-inducing ligand (TRAIL) are more cytotoxic than soluble recombinant TRAIL in sarcoma. Int J Mol Sci 2018; 19: 1449.
27. Kretz AL, von Karstedt S, Hillenbrand A, et al. Should we keep walking along the trail for pancreatic cancer treatment? Revisiting TNF-related apoptosis-inducing ligand for anticancer therapy. Cancers (Basel) 2018; 10: 77.
28. Matsui TA, Sowa Y, Yoshida T, et al. Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis 2006; 27: 1768-77.
29. Liu G, Yu MY, Huang X, et al. Synergistic effect of celecoxib in tumor necrosis factor?related apoptosis?inducing ligand treatment in osteosarcoma cells. Mol Med Rep 2014; 10: 2198-202.
30. Qian H, Chen Y, Huang T, et al. Combined application of embelin and tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and invasion in osteosarcoma cells via caspase-induced apoptosis. Oncol Lett 2018; 15: 6931-40.
31. Li B, Chen R, Chen L, et al. Effects of DDIT4 in Methamphetamine-induced autophagy and apoptosis in dopaminergic neurons. Mol Neurobiol 2017; 54: 1642-60.
32. Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther 2016; 16: 543-56.
33. Jiang X, Zhang Z, Song C, et al. Glaucocalyxin a reverses EMT and TGF-β1-induced EMT by inhibiting TGF-β1/Smad2/ 3 signaling pathway in osteosarcoma. Chem Biol Interact 2019; 307: 158-66.
34. Shen S, Huang K, Wu Y, et al. A miR-135b-TAZ positive feedback loop promotes epithelial-mesenchymal transition (EMT) and tumorigenesis in osteosarcoma. Cancer Lett 2017; 407: 32-44.
35. Ghosh N, Hossain U, Mandal A, Sil PC. The Wnt signaling pathway: a potential therapeutic target against cancer. Ann N Y Acad Sci 2019; 1443: 54-74.
36. Vijayakumar S, Liu G, Rus IA, et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell 2011; 19: 601-12.
37. Zhang W, Duan N, Zhang Q, et al. DNA methylation mediated down-regulation of miR-370 regulates cell growth through activation of the Wnt/β-catenin signaling pathway in human osteosarcoma cells. Int J Biol Sci 2017; 13: 561-73.
38. Zimmerman ZF, Kulikauskas RM, Bomsztyk K, Moon RT, Chien AJ. Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One 2013; 8: e69593.
39. Danieau G, Morice S, Rédini F, Verrecchia F, Royer BB. New insights about the Wnt/β-catenin signaling pathway in primary bone tumors and their microenvironment: a promising target to develop therapeutic strategies. Int J Mol Sci 2019; 20: 3751.
40. Hsieh CH, Hsu HH, Shibu MA, et al. Down-regulation of β-catenin and the associated migration ability by Taiwanin C in arecoline and 4-NQO-induced oral cancer cells via GSK-3β activation. Mol Carcinog 2017; 56: 1055-67.
41. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010; 220: 24-33.
42. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.
43. Sha L, Ma D, Chen C. Exosome-mediated Hic-5 regulates proliferation and apoptosis of osteosarcoma via Wnt/β-catenin signal pathway. Aging (Albany NY) 2020; 12: 23598-608.
44. Pai SG, Carneiro BA, Mota JM, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol 2017; 10: 101.
45. Yadav PS, Feng S, Cong Q, Kim H, Liu Y, Yang Y. Stat3 loss in mesenchymal progenitors causes Job syndrome-like skeletal defects by reducing Wnt/β-catenin signaling. Proc Natl Acad Sci USA 2021; 118: e2020100118.
Options
Outlines

/

〈 〉